Meta-Analysis
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Feb 15, 2025; 16(2): 101282
Published online Feb 15, 2025. doi: 10.4239/wjd.v16.i2.101282
Renal effects and safety of tirzepatide in subjects with and without diabetes: A systematic review and meta-analysis
ABM Kamrul-Hasan, Shinjan Patra, Deep Dutta, Lakshmi Nagendra, AFM Muntahi-Reza, Sanja Borozan, Joseph M Pappachan
ABM Kamrul-Hasan, Department of Endocrinology, Mymensingh Medical College, Mymensingh 2200, Dhaka, Bangladesh
Shinjan Patra, Department of Endocrinology and Metabolism, All India Institute of Medical Sciences Nagpur, Nagpur 441108, Maharashtra, India
Deep Dutta, Department of Endocrinology, CEDAR Superspeciality Clinics, Dwarka, New Delhi 110075, India
Lakshmi Nagendra, Department of Endocrinology, JSS Medical College, JSS Academy of Higher Education & Research, Mysore 570015, India
AFM Muntahi-Reza, Department of Urology, Bangabandhu Sheikh Mujib Medical University, Dhaka 1000, Bangladesh
Sanja Borozan, Department of Endocrinology, Clinical Centre of Montenegro, Podgorica 81000, Montenegro
Sanja Borozan, Faculty of Medicine, University of Montenegro, Podgorica 81000, Montenegro
Joseph M Pappachan, Department of Endocrinology and Metabolism, Lancashire Teaching Hospitals NHS Trust & Manchester Metropolitan University, Preston PR2 9HT, United Kingdom
Joseph M Pappachan, Faculty of Science, Manchester Metropolitan University, Manchester M15 6BH, United Kingdom
Joseph M Pappachan, Department of Endocrinology, Kasturba Medical College, Manipal University, Manipal 576104, India
Author contributions: Kamrul-Hasan ABM contributed to the design, statistical analyses, performance of the research, implementation of the study and the writing of the manuscript; Patra S and Dutta D contributed to the statistical analyses, performance of the research and the writing of the manuscript; Nagendra L, Muntahi-Reza AFM and Borozan S contributed to the quality and professional revision and the writing of the manuscript; Pappachan JM supervised the manuscript preparation and editing the work in the final form.
Conflict-of-interest statement: There are no conflicts of interest among authors in relation to this work.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Joseph M Pappachan, Consultant Endocrinologist, Professor, Department of Endocrinology and Metabolism, Lancashire Teaching Hospitals NHS Trust & Manchester Metropolitan University, Sharoe Green Lane, Lower Ormond St, Preston PR2 9HT, United Kingdom. drpappachan@yahoo.co.in
Received: September 9, 2024
Revised: November 13, 2024
Accepted: December 11, 2024
Published online: February 15, 2025
Processing time: 111 Days and 14.2 Hours
Core Tip

Core Tip: It is important to appraise the renal impacts and safety profile of Tirzepatide for optimal use of this molecule by clinicians for managing patients with type 2 diabetes (T2D), the most common cause of chronic kidney disease across the globe. Based on 15 randomized controlled trials (RCTs) with mostly low risk of bias involving 14471 participants, this systematic review identified that Tirzepatide significantly reduces urine albumin-to-creatinine ratio compared to placebo and insulin, with a neutral impact on estimated glomerular filtration rate (eGFR) in individuals with T2D and obesity without T2D. Moreover, tirzepatide does not appear to increase the risks of renal adverse events. Larger and longer-term RCTs are warranted to prove the renal benefits of tirzepatide and its potential to prevent eGFR decline in patients.